What types of risks are typically identified in a clinical trial risk management plan?

Common risks include patient-related risks such as adverse effects, trial design flaws, compliance issues with regulatory standards, data management errors, and site-specific challenges.

How often should a clinical trial risk management plan be reviewed?

The RMP should be reviewed regularly throughout the trial, especially after key milestones or when new information arises that could affect the identified risks.

Who is responsible for developing and managing the clinical trial risk management plan?

Typically, the sponsor or the clinical research organization (CRO) leads the development of the RMP, but it should be a collaborative effort involving all stakeholders.

Why is transparency important in the context of clinical trials?

Transparency fosters trust among participants, regulatory bodies, and the broader community. To explore the significance of transparency in clinical trials, check out our in-depth article on the importance of trial transparency in fostering community trust.